• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

    69.53 +4.18 (+6.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 51,532
    Open 65.35
    Bid (Size) 66.00 (100)
    Ask (Size) 70.00 (200)
    Prev. Close 65.35
    Today's Range 64.28 - 69.53
    52wk Range 0.0786 - 240.00
    Shares Outstanding 40,710,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
    From Spruce Biosciences, Inc.
    Via Business Wire

    Performance

    YTD
    -23.3%
    -23.3%
    1 Month
    +28.3%
    +28.3%
    3 Month
    -20.2%
    -20.2%
    6 Month
    +681.2%
    +681.2%
    1 Year
    +25815.0%
    +25815.0%

    More News

    Read More
    News headline image
    Spruce Biosciences to Present at Upcoming Investor Conferences in March
    From Spruce Biosciences, Inc.
    Via Business Wire
    SPRB Stock Hits 19-Month High Amid Trading Halts ↗
    Via Stocktwits
    Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside ↗
    Via Stocktwits
    News headline image
    SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗
    Via Stocktwits
    News headline image
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Inc (NASDAQ:SPRB) Reports Q3 2025 Results, Secures $50M Financing and Breakthrough Therapy Designation ↗
    Via Chartmill
    News headline image
    Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Spruce Biosciences Announces $50.0 Million Private Placement Financing
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga

    Frequently Asked Questions

    Is Spruce Biosciences, Inc. - Common Stock publicly traded?
    Yes, Spruce Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Spruce Biosciences, Inc. - Common Stock trade on?
    Spruce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Spruce Biosciences, Inc. - Common Stock?
    The ticker symbol for Spruce Biosciences, Inc. - Common Stock is SPRB on the Nasdaq Stock Market
    What is the current price of Spruce Biosciences, Inc. - Common Stock?
    The current price of Spruce Biosciences, Inc. - Common Stock is 69.53
    When was Spruce Biosciences, Inc. - Common Stock last traded?
    The last trade of Spruce Biosciences, Inc. - Common Stock was at 04/01/26 04:00 PM ET
    What is the market capitalization of Spruce Biosciences, Inc. - Common Stock?
    The market capitalization of Spruce Biosciences, Inc. - Common Stock is 2.83B
    How many shares of Spruce Biosciences, Inc. - Common Stock are outstanding?
    Spruce Biosciences, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.